Topical haemoglobin spray for XXXX .

@entity1 @entity26 @entity4760
UNASSIGNED: The development and subsequent deterioration of @entity4760 ( @entity4760 ) is a common occurrence across all healthcare divides, concerning all @entity1 groups, age, gender and social environments. It increases demand on clinical resources and creates unnecessary hardship for @entity1 . Chronic @entity4760 is challenging to prevent and notoriously difficult to manage owing to the complex nature of the @entity1 and the disease itself. The improvement of oxygenation to many chronic wound groups is gaining momentum across wound care; particularly in those wounds such as @entity4760 that present with circulatory, @entity26 -deficient scenarios. METHOD: A descriptive evaluation was undertaken in an acute clinical setting where a spray solution containing purified haemoglobin was used in a cohort of 20 @entity1 who presented with chronic (>12 weeks) @entity4760 . Standard wound care was undertaken by 18 health professionals with no changes to products, devices or practice before evaluation. All wounds received the addition of the product on eight set occasions over a 4-week period and the resulting data correlated in regards to the set outcomes of wound surface area reduction, ease of use, adverse events and @entity1 acceptability. RESULTS: At 4 weeks all wounds had demonstrated positive wound reduction, there were no adverse events, all @entity1 and clinicians found the product acceptable and easy to use. Interestingly, although not a set outcome, all wounds commenced the evaluation with wound-bed slough present and at 4 weeks 100% were deemed slough free. At a further 4-week review no @entity1 wounds had regressed. CONCLUSION: The incorporation of a haemoglobin spray solution within this cohort of @entity4760 resulted in a positive improvement in wound healing and slough elimination. Further work in this area is recommended to increase the evidence.
